Clinical Trials
3 trialsNCT01311713 2024-01-30
Study to Determine the Maximum Tolerated Dose of the PARP Inhibitor CEP-9722 in Participants With Solid Tumors
Teva Branded Pharmaceutical Products R&D, Inc.
Phase 1/2 Terminated
NCT04774627 2021-09-23
Pancytopenia Related to PARP Inhibitors (PancytoRIB)
University Hospital, Caen
Completed
NCT04326023 2021-03-11
Myelodysplastic Syndrome and Acute Myeloid Leukemia Related to PARP Inhibitors (MyeloRIB)
University Hospital, Caen
Completed